Clinical Trial Update: Rosiglitazone Effect on Mitochondria and Lipoatrophy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rosiglitazone's effects on mitochondria and lipoatrophy in HIV infections; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hiv-associated Lipodystrophy

Drugs mentioned

• Rosiglitazone (rosiglitazone)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 2 | Status: COMPLETED | Results posted: 2017-02-06